Metabolic Regulation Peptides Bioactive Toxin-Derived Peptides Tumor-Associated Antigen Peptides Nuclear Localization Signals (NLS) Cell-Penetrating Peptides (CPPs) Neurodegenerative Disease Research Peptides Melanogenesis Modulation Anti-Aging & Skin Remodeling Gastrin, GRP & Bombesin Peptides Somatostatin Analogs DPPIV/CD26 Peptides Kinase Activity Modulators Caspase Substrates & Inhibitors Viral Protease Substrates Antiviral Peptides Antimicrobial Peptides Cardiovascular Peptides Immunomodulatory Peptides Calcitonin & CGRP Family Peptides Incretin & Metabolic Peptides Parathyroid Hormone (PTH) Growth Hormone GnRH Analogues/Antagonists Pain and Inflammation Modulation Pituitary Hormones Neurotransmitters/Neuropeptides Standard Fmoc-Amino Acids D-Form Amino Acids Resins Peptide Coupling Reagents & Additives Specialty Peptide Building Blocks Pseudoproline Dipeptides Phenylalanine & Tryptophan Unusual Amino Acids & Analogs Newly Launched Small-Molecule Specialties Impurity Analysis & Bioactivity Research Special Offers Peptide Synthesis Chemical Synthesis ADMET Profiling Service AlanMolecularAI AlanDockAI Linear Peptide Optimization Cyclic Peptide Optimization Task Management Knowledge Center News About Us Reagents & Custom Orders Aipower Platform
Sign in
Cart
Search
Home Product Peptide Catalog Products Hormonal & Endocrine Regulatory Peptides GnRH Analogues/Antagonists Cetrorelix Acetate | Peptide GnRH Receptor Antagonist

DESCRIPTION

Cetrorelix acetate is a synthetic decapeptide antagonist of the gonadotropin-releasing hormone receptor. Unlike GnRH agonists, it inhibits receptor activation through direct competition with GnRH rather than first stimulating the receptor and relying on subsequent desensitization.

Its sequence incorporates multiple D-amino acids and non-proteinogenic residues designed to create high-affinity receptor binding without productive receptor activation.

Product Information

PropertySpecification
Product NameCetrorelix Acetate
CAS No.130143-01-0
Condensed SequenceAc-D-2Nal-D-Phe(4-Cl)-D-3Pal-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH₂
Peptide Length10 amino-acid residues
Peptide FormulaC70H92ClN17O14
Peptide Moiety Molecular WeightApproximately 1431.0 Da
Reference Acetate FormDiacetate
Reference Diacetate FormulaC74H100ClN17O18
Reference Diacetate Molecular WeightApproximately 1551.2 Da
N-TerminusAcetylated
C-TerminusD-Ala-NH₂
Primary TargetGnRH receptor / GNRHR
Pharmacological RoleCompetitive GnRH receptor antagonist

A Heavily Engineered Antagonist Sequence

Cetrorelix differs substantially from native GnRH. Its N-terminal region contains D-2Nal, 4-chloro-D-Phe and D-3Pal, introducing bulky aromatic and heteroaromatic side chains into positions important for receptor recognition.

The sequence also contains D-Cit6 and D-Ala10 together with N-terminal acetylation and C-terminal amidation.

These modifications create a peptide optimized for receptor occupancy without inducing the same active receptor conformation produced by GnRH agonists.

Competitive Blockade Without Agonist Pretreatment

Cetrorelix competes with endogenous GnRH for the pituitary receptor and inhibits downstream gonadotropin signaling in a concentration-dependent manner.

Because its mechanism is antagonistic, receptor blockade does not require an initial phase of agonist stimulation or prolonged receptor desensitization.

This distinction makes Cetrorelix useful for experiments where researchers need relatively direct interruption of GnRH-dependent signaling.

Antagonist Binding and Receptor Conformation

Mutagenesis studies of the human GnRH receptor indicate that agonists and peptide antagonists occupy overlapping but non-identical interaction networks within the receptor-binding pocket.

The bulky hydrophobic N-terminal residues of Cetrorelix contribute to receptor binding while failing to stabilize the active G-protein-coupled receptor conformation characteristic of agonist ligands.

Additional studies have also shown that Cetrorelix can influence receptor internalization behavior, illustrating that peptide antagonism can involve more than simple steric competition.

Cetrorelix Versus GnRH Agonists

FeatureCetrorelixGnRH Agonists
Primary ActionCompetitive receptor blockadeReceptor activation
Initial Agonist SignalingNot requiredPresent
Long-Term Suppression MechanismContinued antagonist occupancyDesensitization/down-regulation
Sequence TypeHighly modified decapeptideModified GnRH agonist scaffold

Experimental and Quality Considerations

Cetrorelix contains several non-standard amino-acid residues, making molecular identity particularly important. Correct stereochemistry, chlorinated phenylalanine, pyridylalanine and citrulline incorporation should be considered together with purity.

Our Peptide Quality Control capabilities support LC-MS and analytical HPLC according to the selected specification.

Custom antagonist substitutions or GnRH-derived analogs can be evaluated through Chemical Peptide Synthesis.

Frequently Asked Questions

Is Cetrorelix an agonist or antagonist?

Cetrorelix is a competitive GnRH receptor antagonist.

Does Cetrorelix require receptor desensitization before blocking GnRH signaling?

No. It directly competes with GnRH for receptor binding.

Why does the sequence contain several D-amino acids?

D-stereochemistry and non-natural side chains help create a receptor-binding geometry and stability profile distinct from native GnRH.

Research Use Only.

Cetrorelix Acetate | Peptide GnRH Receptor Antagonist

Catalog No: AS2505
Cas No: 130143-01-0

{{ getShowPrice() }} {{ getPrice() }}

Add to Cart Bulk Inquiry
{{ isCollect ? 'Cancel collection' : 'Collection' }}

Related Products

Submit